Lifibrol, identified by its CAS number 96609-16-4, is a chemical compound that has been studied primarily for its potential therapeutic applications. It is classified as a selective serotonin reuptake inhibitor (SSRI), which suggests that it may influence serotonin levels in the brain, potentially impacting mood and anxiety disorders. Lifibrol has been investigated for its effects on various physiological processes, including its role in modulating neurotransmitter activity. The compound is characterized by its specific molecular structure, which contributes to its pharmacological properties. In terms of safety and toxicity, like many SSRIs, Lifibrol may have side effects, and its use should be monitored in clinical settings. Research into Lifibrol's efficacy and safety profile continues, as it may offer insights into new treatment options for mental health conditions. However, as with any pharmaceutical agent, comprehensive clinical trials and regulatory evaluations are essential to establish its therapeutic potential and safety for human use.

Lifibrol

96609-16-4: Lifibrol [USAN:INN],  UNII-6KWX9X0Q5K,  K 12148,  (+-)-p-(4-(p-tert-Butylphenyl)-2-hydroxybutoxy)benzoic acid,  Lifibrolum,  4-[4-(4-tert-butylphenyl)-2-hydroxybutoxy]benzoic acid,  Benzoic acid, 4-(4-(4-(1,1-dimethylethyl)phenyl)-2-hydroxybutoxy)-, (+-)-,  Lifibrolum [INN-Latin]

Lifibrol (U-83860) is an inhibitor of cholesterol synthesis.Lifibrol has anticholesterol and hypolipidemic properties and promotes the conversion of LDL Apo B-

CAS 96609-16-4: Lifibrol

Lifibrol

Ref: TM-T27832

Lifibrol

Ref: 54-BUP11610

Benzoic acid, 4-[4-[4-(1,1-dimethylethyl)phenyl]-2-hydroxybutoxy]-

Ref: IN-DA00IJU9